MR and Gal-3 inhibitors might be promising therapeutic options to palliate cytokine inflammatory storm in COVID-19 patients and its long-term clinical impact including pulmonary fibrosis [33,40]. Here, LGALS3 is linked to pulmonary fibrosis.